NaviGate Cardiac Structures Inc. (“NCSI”) reports “excellent valvular function” at 1-year follow-up of first patient to receive GATE™ tricuspid valved stent via transjugular access


May 29, 2018   •  Press Release

LAKE FOREST, Calif.--(BUSINESS WIRE)--NaviGate Cardiac Structures Inc. (“NCSI”) announced today that the first patient to receive its replacement tricuspid valved stent via transjugular access has reached one-year post-procedure with excellent valvular function. This patient, along with 15 others treated to date under compassionate use protocols for severe tricuspid regurgitation, have received NCSI’s GATE™ tricuspid valved stent designed to lead to restored valvular function and…

Continue Reading

Quebec University in Laval, Canada. This is the first tricuspid valve replacement in Canada.


Feb 12, 2018   •  Press Release

Communiqué de presse PREMIÈRE MÉDICALE CANADIENNE : UN 10E CAS DE REMPLACEMENT TRICUSPIDE PERCUTANÉ AU MONDE RÉALISÉ À L’INSTITUT Québec, 8 février 2018 – L’Institut universitaire de cardiologie et de pneumologie de Québec– Université Laval (l’Institut) a récemment procédé avec succès à un premier cas deremplacement tricuspide percutané. Jusqu’à maintenant, seulement 10 patients dans le mondeont subi ce type de remplacement percutané. La procédure a été…

Continue Reading

NaviGate Cardiac Structures, Inc. Reports “Exceptional” Six-Week Results for Two Implantations of Its GATE™ Atrioventricular Valved Stent (AVS)


Nov 29, 2017   •  Business Wire

LAKE FOREST, Calif. — NaviGate Cardiac Structures Inc. ("NCSI") announced today "exceptional results" for implantation of its GATE™ catheter-guided tricuspid atrioventricular valved stent (AVS) at six-week follow-up in two nonagenarian patients presenting with severe tricuspid valve insufficiency. Implantations of the GATE™ AVS were performed at New York-Presbyterian/Columbia University…

View Press Release

FOR IMMEDIATE RELEASE - Contact: Ronald Trahan, APR, Ronald Trahan Associates, 1 (508) 359-4005, x108

NaviGate Cardiac Structures, Inc. (“NCSI”) reports world’s first successful transcatheter implantation of 52-mm tricuspid valve into a transplanted-heart patient


Aug 30, 2017   •  Business Wire

LAKE FOREST, Calif., Aug. 30, 2017 - NaviGate Cardiac Structures Inc. ("NCSI") announced today that its GATE™ catheter-guided tricuspid atrioventricular valved stent (A VS) was implanted through the jugular vein six weeks ago into a patient's transplanted heart that was failing due to severe tricuspid valve insufficiency. The successful implantation of the GATE™ A VS at the Policlinico of the…

View Press Release

FOR IMMEDIATE RELEASE - Contact: Ronald Trahan, APR, Ronald Trahan Associates, 1 (508) 359-4005, x108

NaviGate Cardiac Structures, Inc. (“NCSI”) reports first heterotopic transcatheter GATE™ tricuspid valved stent successful implantation


Apr 26, 2017   •  Press Release

LAKE FOREST, Calif., Apr, 26, 2017 - NaviGate Cardiac Structures Inc. (“NCSI”) announced today that the GATE™ catheter-guided tricuspid atrioventricular valved stent (AVS) was implanted through the jugular vein one week ago in a patient suffering from severe tricuspid regurgitation stemming from two failed tricuspid annuloplasty rings that were unable to maintain the patient’s valve competence. The patient, a 78-year-old man with a long history of cardiac conditions, has undergone…

Continue Reading

NaviGate Cardiac Structures Inc. (“NCSI”) reports world’s first transcatheter tricuspid valved stent is successfully implanted


Dec 30, 2016   •  Business Wire

LAKE FOREST, Calif., Dec. 30, 2016 — NaviGate Cardiac Structures Inc. ("NCSI") announced today that a novel valved stent that can capture the enlarged annulus in patients suffering from functional tricuspid regurgitation (FTR) was implanted in a patient presenting with massive incompetence of the tricuspid valve. The patient, a 64-year-old female with an extensive history of severe tricuspid…

View Press Release

FOR IMMEDIATE RELEASE - Contact: Ronald Trahan, APR, Ronald Trahan Associates, 1 (508) 359-4005, x108